# Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

> **NCT02856568** · PHASE1 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Non-Resectable Cholangiocarcinoma
- Recurrent Cholangiocarcinoma
- Stage III Extrahepatic Bile Duct Cancer
- Stage III Intrahepatic Cholangiocarcinoma
- Stage IIIA Hilar Cholangiocarcinoma
- Stage IIIB Hilar Cholangiocarcinoma
- Stage IVA Extrahepatic Bile Duct Cancer
- Stage IVA Hilar Cholangiocarcinoma
- Stage IVA Intrahepatic Cholangiocarcinoma
- Stage IVB Extrahepatic Bile Duct Cancer
- Stage IVB Hilar Cholangiocarcinoma
- Stage IVB Intrahepatic Cholangiocarcinoma
- Unresectable Extrahepatic Bile Duct Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Ricolinostat

## Key facts

- **NCT ID:** NCT02856568
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05-01
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Site dropped study
- **Last updated:** 2017-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02856568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02856568, "Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02856568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*